InfuSystem faces a challenging outlook as revenue growth turned negative at -3.0% in 2026Q1, highlighting the difficulty of scaling its core oncology and equipment rental segments. While the company has successfully reduced its total debt to $22.8 million from...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.15+42.9% vs $0.10 | $37M+1.6% vs $36M |
Q2 2026 May 7, 2026 | $0.05+25.0% vs $0.04 | $34M-1.9% vs $34M |
Q1 2026 Feb 24, 2026 | $0.10+42.9% vs $0.07 | $36M-1.2% vs $37M |
Q4 2025 Nov 4, 2025 | $0.11+37.5% vs $0.08 | $36M-0.5% vs $37M |
Guardant Health (NASDAQ: GH - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Earnings and Valuation This table compares Guardant Health and
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Host Investor Webcast on September 24, 2026.
Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Exagen and InfuSystem"s
BlackRock Inc. bought a new position in shares of InfuSystem Holdings, Inc. (NYSE: INFU) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,585,415 shares of the company's stock, valued at approximately $15,299,000. BlackRock Inc. owned approximately 7.86% of InfuSystem
Benchmark INFU against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for InfuSystem Holdings, Inc. (INFU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.70 | $256.31M | 40.97 | 6.36% | 4.62% | 11.54% | — | |
| $13.84 | $260.5M | -20.97 | 1.46% | -13.09% | -7.46% | — | |
| $21.25 | $1.46B | 26.23 | 7.08% | 6.59% | 24.12% | — | |
| $7.60 | $142.61M | 28.15 | 18.78% | 4.66% | 3.6% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $32.99 | $1.5B | 744.70 | 6.53% | 3.13% | 3.13% | — |
InfuSystem Holdings, Inc. (INFU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
InfuSystem Holdings, Inc. (INFU) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Aug 4, 2026·SEC
Jul 28, 2026·SEC
Get notified when INFU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
InfuSystem Holdings, Inc. (INFU) stock FAQ — growth, dividends, profitability & financials explained
InfuSystem Holdings, Inc. (INFU) reported $143.3M in revenue for fiscal year 2025.
InfuSystem Holdings, Inc. (INFU) grew revenue by 6.4% over the past year. This is steady growth.
Yes, InfuSystem Holdings, Inc. (INFU) is profitable, generating $8.5M in net income for fiscal year 2025 (4.6% net margin).
InfuSystem Holdings, Inc. (INFU) has a return on equity (ROE) of 11.5%. This is reasonable for most industries.
InfuSystem Holdings, Inc. (INFU) generated $19.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
